Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Trastuzumab

Pertuzumab

Mitogens

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion

trastuzumab

pertuzumab

Norman Wolmark, MD

This study is a biospecimen discovery project that will serve as a pilot for a comprehensive 'omics approach using fresh core biopsy tissue and blood samples for DNA and protein analysis, as well as paired tumor-normal exome DNA and RNA sequencing.

This study will be conducted at select NSABP sites where investigators are willing to give paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination as the initial component of neoadjuvant therapy as a pilot for a comprehensive 'omics approach using next generation sequencing and protein expression and post-translational modification analysis using mass spectrometry (MS) based and Reverse Phase Protein Array-based proteomics. Tumor samples will be obtained at baseline and 48 to 72 hours after initial drug treatment to study variation in the biological responses to these agents. The study of tumors both before and early after the first treatment probes the biological responses to treatment and is rich source of predictive biomarkers.

NSABP Biospecimen Discovery Project

Breast Cancer Research Foundation

Washington University School of Medicine

NSABP Foundation Inc

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
NSABP Biospecimen Discovery Project	NCT01850628	Breast Cancer	Paclitaxel trastuzumab pertuzumab	18 Years -	NSABP Foundation Inc
NSABP Biospecimen Discovery Project	NCT01850628	Breast Cancer	Paclitaxel trastuzumab pertuzumab	18 Years -	NSABP Foundation Inc

Spots Global Cancer Trial Database for her2 positive (human epidermal growth factor receptor 2)